ArriVent BioPharma, Inc. AVBP
Set alert
As of Nov 2, 11:20 AM ET
- YTD
- -31.68%
- 1 year
- -26.61%
- Open
- 14.89
- Prev close
- 14.87
- Mkt cap
- 677.98M
- Vol
- 202.55K
- Avg vol
- 1.19M
- EPS
- -3.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.66
- High
- 14.98
- Forward P/E
- -5.64
- Beta
- 1.35
- Short ratio
- 13.52
- Inst. own
- 100.41%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 16, 2026
- 50-d avg
- 26.34
- 200-d avg
- 27.09
- 1y target
- 22.30
3M chart
Events in this range
- Aug 12, 2026Earnings: -1.05; estimate -0.98732; surprise -6.35%
- Oct 7, 2026Rating: Truist Securities · Buy → Buy
- Oct 7, 2026Rating: Jones Trading · Buy → Buy
- Oct 7, 2026Rating: Citigroup · Buy → Buy
- Oct 8, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 16, 2026Rating: BTIG · Buy → Buy
- Oct 20, 2026Rating: B. Riley Securities · Buy → Buy
Signals (22)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Oct 6, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Sep 30, 2026 | 1 month ago |
| SMA: Bullish | Sep 30, 2026 | 1 month ago |
| SMA: Bearish | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 22, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Sep 2, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 25, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 14, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 3 months ago |
Key statistics
- Market cap
- 1.04B
- Enterprise value
- 573.94M
- Trailing P/E
- 0.00
- Forward P/E
- -5.64
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.77
- EPS (TTM)
- -3.62
- Beta
- 1.35
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -89.48M
- Total cash
- 373.12M
- Total debt
- 351.00K
- Return on equity
- -53.25%
- Shares outstanding
- 49.31M
- Short % of float
- 18.18%
- 50-day average
- 26.34
- 200-day average
- 27.09
Analyst view
Consensus: strong buy
- Target (low)
- 15.00
- Target (mean)
- 22.30
- Target (high)
- 29.00
- Strong buy0
- Buy11
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 16, 2026
Expected Nov 16, 2026. Consensus EPS estimate -1.07.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 16, 2026 | Sep 30, 2026 | -1.04 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.98732 | -1.05 | -0.06 | -6.35% |
| May 11, 2026 | Mar 31, 2026 | -0.88 | -0.96 | -0.08 | -9.09% |
| Mar 5, 2026 | Dec 31, 2025 | -0.87 | -0.78 | +0.09 | +10.34% |
| Nov 10, 2025 | Sep 30, 2025 | -0.78 | -0.83 | -0.05 | -6.41% |
| Aug 11, 2025 | Jun 30, 2025 | -0.70 | -0.90 | -0.20 | -28.57% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 20, 2026 | B. Riley Securities | main | Buy | Buy |
| Oct 16, 2026 | BTIG | reit | Buy | Buy |
| Oct 8, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 7, 2026 | Citigroup | main | Buy | Buy |
| Oct 7, 2026 | Jones Trading | main | Buy | Buy |
| Oct 7, 2026 | Truist Securities | main | Buy | Buy |
About ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- arrivent.com
News
- Arrivent Biopharma Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your AVBP Investments
- Guggenheim Maintains Buy on ArriVent BioPharma, Raises Price Target to $30
- ArriVent BioPharma's ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Why Surgery Partners Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
- ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
- ArriVent BioPharma To Present Initial Safety, Efficacy Results Of Its Phase 1 Trial Of CDH17-Targeted ADC ARR-217 In Participants With Gastrointestinal Cancers At ESMO Congress 2026
- ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
- ARRIVENT BIOPHARMA AVBP INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 47.3% Share Drop
- B. Riley Securities Maintains Buy on ArriVent BioPharma, Lowers Price Target to $29
Your note
Sign in to keep a note on AVBP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | Beneficial Owner of more than 10% of a Class of Security | Sale | Dec 9, 2025 | 0 |
| LACHAPELLE ROBIN | Chief Operating Officer | Conversion of Exercise of derivative security | Jul 10, 2025 | 530,213 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Montanova Capital LLC | 9.16% | 4,515,531 | 94.83M | Jun 29, 2026 |
| Infinitum Asset Management, LLC | 9.00% | 4,438,384 | 93.21M | Jun 29, 2026 |
| HHLR Advisors, LTD | 7.97% | 3,929,117 | 82.51M | Jun 29, 2026 |
| Blackrock Inc. | 6.59% | 3,250,396 | 68.26M | Jun 29, 2026 |
| Orbimed Advisors LLC. | 6.14% | 3,027,328 | 63.57M | Jun 29, 2026 |
| FMR, LLC | 5.64% | 2,778,959 | 58.36M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.72% | 1,338,764 | 28.11M | Jun 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 2.68% | 1,320,503 | 27.73M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.97% | 970,012 | 20.37M | Aug 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.86% | 918,618 | 19.29M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.84% | 414,872 | 8.71M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.81% | 397,078 | 8.34M | Jun 29, 2026 |